Simulations Plus Future Growth

Future criteria checks 3/6

Simulations Plus is forecast to grow earnings and revenue by 73.7% and 9% per annum respectively while EPS is expected to grow by 72.1% per annum.

Key information

73.7%

Earnings growth rate

72.08%

EPS growth rate

Healthcare Services earnings growth	19.1%
Revenue growth rate	9.0%
Future return on equity	n/a
Analyst coverage	Good
Last updated	30 Sep 2025

Recent future growth updates

Recent updates

The Bottom Fishing Club - Simulations Plus: Huge Potential In AI Drug Discovery

Sep 22

Some Simulations Plus, Inc. (NASDAQ:SLP) Shareholders Look For Exit As Shares Take 25% Pounding

Jul 31

Simulations Plus, Inc.'s (NASDAQ:SLP) Stock Retreats 36% But Earnings Haven't Escaped The Attention Of Investors

Jun 13

Are Investors Undervaluing Simulations Plus, Inc. (NASDAQ:SLP) By 28%?

May 07

Simulations Plus: Benefiting From FDA Modernization And AI

Apr 16

Simulations Plus, Inc.'s (NASDAQ:SLP) 25% Jump Shows Its Popularity With Investors

Apr 13

Why Investors Shouldn't Be Surprised By Simulations Plus, Inc.'s (NASDAQ:SLP) 29% Share Price Surge

Feb 08

Capital Allocation Trends At Simulations Plus (NASDAQ:SLP) Aren't Ideal

Jan 08

We Think Simulations Plus' (NASDAQ:SLP) Healthy Earnings Might Be Conservative

Nov 07

Biosimulation Innovations And Tactical Acquisitions To Boost Drug Development Growth

Oct 27 Integration and expansion into new markets drive revenue growth and improved profitability through increased efficiencies and enhanced offerings.

Simulations Plus: Questionable Whether It Will Benefit Or Be Hurt By Generative AI

Feb 01

We Like Simulations Plus' (NASDAQ:SLP) Earnings For More Than Just Statutory Profit

Jan 12

Capital Allocation Trends At Simulations Plus (NASDAQ:SLP) Aren't Ideal

Nov 06

Estimating The Intrinsic Value Of Simulations Plus, Inc. (NASDAQ:SLP)

Sep 06

Earnings and Revenue Growth Forecasts

NasdaqGS:SLP - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
8/31/2028	100	12	17	N/A	2
8/31/2027	87	11	12	N/A	5
8/31/2026	80	9	10	N/A	7
8/31/2025	78	-65	-56	N/A	7
5/31/2025	80	-63	11	14	N/A
2/28/2025	79	7	8	12	N/A
11/30/2024	74	8	8	12	N/A
8/31/2024	70	10	9	13	N/A
5/31/2024	67	10	10	15	N/A
2/29/2024	65	11	13	18	N/A
11/30/2023	62	11	13	17	N/A
8/31/2023	60	10	18	22	N/A
5/31/2023	56	10	22	27	N/A
2/28/2023	54	10	18	22	N/A
11/30/2022	53	11	15	19	N/A
8/31/2022	54	12	14	18	N/A
5/31/2022	52	12	14	18	N/A
2/28/2022	50	12	14	19	N/A
11/30/2021	48	10	12	17	N/A
8/31/2021	46	10	15	19	N/A
5/31/2021	46	12	12	16	N/A
2/28/2021	46	11	10	14	N/A
11/30/2020	43	10	11	14	N/A
8/31/2020	42	9	8	11	N/A
5/31/2020	40	9	6	9	N/A
2/29/2020	38	9	8	10	N/A
11/30/2019	36	9	10	12	N/A
8/31/2019	34	9	10	12	N/A
5/31/2019	33	8	10	12	N/A
2/28/2019	31	7	N/A	11	N/A
11/30/2018	30	9	N/A	9	N/A
8/31/2018	30	9	N/A	9	N/A
5/31/2018	29	9	N/A	8	N/A
2/28/2018	27	8	N/A	9	N/A
11/30/2017	26	6	N/A	8	N/A
8/31/2017	24	6	N/A	7	N/A
5/31/2017	22	5	N/A	7	N/A
2/28/2017	21	5	N/A	6	N/A
11/30/2016	21	5	N/A	8	N/A
8/31/2016	20	5	N/A	5	N/A
5/31/2016	20	5	N/A	6	N/A
2/29/2016	20	5	N/A	6	N/A
11/30/2015	19	4	N/A	7	N/A
8/31/2015	18	4	N/A	7	N/A
5/31/2015	17	4	N/A	6	N/A
2/28/2015	14	3	N/A	5	N/A
11/30/2014	13	3	N/A	4	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SLP is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.1%).

Earnings vs Market: SLP is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: SLP is expected to become profitable in the next 3 years.

Revenue vs Market: SLP's revenue (9% per year) is forecast to grow slower than the US market (9.8% per year).

High Growth Revenue: SLP's revenue (9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if SLP's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/10/07 21:54
End of Day Share Price	2025/10/07 00:00
Earnings	2025/05/31
Annual Earnings	2024/08/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Simulations Plus, Inc. is covered by 11 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
David Larsen	BTIG
Dane Leone	CGS International
Constantine Davides	Citizens JMP Securities, LLC

Simulations Plus Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Simulations Plus, Inc. Updates Earnings Guidance for the Fiscal Year 2025

Consensus EPS estimates fall by 16%

Consensus EPS estimates fall by 20%

Simulations Plus, Inc. Provides Revenue Guidance for the Third Quarter and Full Year of Fiscal 2025

Price target increased by 9.4% to US$46.60

Simulations Plus, Inc. Provides Earnings Guidance for the Year 2025

Recent updates

Director notifies of intention to sell stock

The Bottom Fishing Club - Simulations Plus: Huge Potential In AI Drug Discovery

Some Simulations Plus, Inc. (NASDAQ:SLP) Shareholders Look For Exit As Shares Take 25% Pounding

Simulations Plus, Inc. and Institute of Medical Biology of the Polish Academy of Sciences Partnership Announces Results in Validation of ADMET Predictor Models with Enhanced AI Drug Design

Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Simulations Plus, Inc. Updates Earnings Guidance for the Fiscal Year 2025

Consensus EPS estimates fall by 16%

Director notifies of intention to sell stock

Investor sentiment deteriorates as stock falls 33%

Consensus EPS estimates fall by 20%

Simulations Plus, Inc.'s (NASDAQ:SLP) Stock Retreats 36% But Earnings Haven't Escaped The Attention Of Investors

New minor risk - Share price stability

Now 34% undervalued after recent price drop

Simulations Plus, Inc. Provides Revenue Guidance for the Third Quarter and Full Year of Fiscal 2025

Simulations Plus, Inc. Releases ADMET Predictor 13

Investor sentiment deteriorates as stock falls 20%

Now 21% undervalued

Simulations Plus, Inc. Releases DILIsym 11

Are Investors Undervaluing Simulations Plus, Inc. (NASDAQ:SLP) By 28%?

Now 28% undervalued after recent price drop

Price target increased by 9.4% to US$46.60

Simulations Plus, Inc. Supports New FDA Roadmap for Reducing Animal Testing in Preclinical Safety Studies

Simulations Plus: Benefiting From FDA Modernization And AI

Simulations Plus, Inc.'s (NASDAQ:SLP) 25% Jump Shows Its Popularity With Investors

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Simulations Plus, Inc. Provides Earnings Guidance for the Year 2025

Simulations Plus, Inc. to Report Q2, 2025 Results on Apr 03, 2025

Investor sentiment deteriorates as stock falls 15%

Why Investors Shouldn't Be Surprised By Simulations Plus, Inc.'s (NASDAQ:SLP) 29% Share Price Surge

Now 21% undervalued

Consensus EPS estimates fall by 38%

First quarter 2025 earnings: EPS misses analyst expectations

Capital Allocation Trends At Simulations Plus (NASDAQ:SLP) Aren't Ideal

Simulations Plus, Inc. Provides Earnings Guidance for the Fiscal 2025

Insufficient new directors

Simulations Plus, Inc., Annual General Meeting, Feb 13, 2025

Simulations Plus, Inc. to Report Q1, 2025 Results on Jan 07, 2025

Investor sentiment improves as stock rises 16%

Simulations Plus, Inc. and University of Connecticut Receive New FDA Grant to Expand Mechanistic Modeling Approaches for Long-Acting Injectables

We Think Simulations Plus' (NASDAQ:SLP) Healthy Earnings Might Be Conservative

Investor sentiment deteriorates as stock falls 16%

Biosimulation Innovations And Tactical Acquisitions To Boost Drug Development Growth

Price target decreased by 7.5% to US$52.75

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Simulations Plus, Inc. Provides Earnings Guidance for Fiscal Year 2025

Simulations Plus, Inc. to Report Q4, 2024 Results on Oct 23, 2024

Simulations Plus and the University of Southern California Secure NIH Grant to Develop New AI Drug Discovery Offerings

Simulations Plus, Inc. Announces Executive Changes, Effective August 30, 2024

Simulations Plus: Declining Margins Are A Problem

Now 21% undervalued after recent price drop

Simulations Plus, Inc. Releases the latest version of its quantitative systems toxicology (QST) platform, DILIsym version X

Upcoming dividend of US$0.06 per share

Simulations Plus: Steady Growth, But What About The Margins?

Consensus EPS estimates fall by 14%

Third quarter dividend of US$0.06 announced

Third quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Simulations Plus, Inc. Updates Earnings Guidance for the Fiscal 2024

Now 12% overvalued after recent price rise

Now 21% overvalued after recent price rise

Simulations Plus, Inc. to Report Q3, 2024 Results on Jul 02, 2024

Consensus EPS estimates fall by 17%, revenue upgraded

Price target increased by 12% to US$60.33

Simulations Plus, Inc. (NasdaqGS:SLP) acquired Pro-ficiency, LLC from NovaQuest Capital Management, L.L.C., QHP Capital, L.P. and Pro-ficiency’s minority shareholders for approximately $100 million.

Simulations Plus Releases GastroPlus® X, The Next Generation PBPK/PBBM Modeling & Simulation Software

Simulations Plus: Reliance On Consulting And Acquisitions Creates Doubts

lead Independent Director notifies of intention to sell stock

Upcoming dividend of US$0.06 per share

Second quarter dividend of US$0.06 announced

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations